Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HYR-PB21 (bupivacaine liposome)
- Development stage
- Phase 4
- Lead developer
- Hengrui Therapeutics
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Parenteral
01
Overview
HYR-PB21 is a liposomal formulation of bupivacaine, a long-acting amide-type local anesthetic. Developed by Jiangsu Hengrui Pharmaceuticals, it is designed for local infiltration to provide extended-duration postoperative analgesia. The formulation utilizes a multivesicular liposome (MVL) delivery system that allows for the sustained release of bupivacaine over a period of up to 72 hours. This prolonged release profile is intended to provide continuous pain relief at the surgical site, potentially reducing the requirement for systemic opioids and improving patient recovery outcomes. HYR-PB21 is currently being evaluated in Phase III clinical trials in China for the management of postoperative pain following procedures such as hemorrhoidectomy.
- Other names
- Bupivacaine liposome injectionLiposomal bupivacaine
02
Targets
CaV (Voltage-gated calcium channel protein complex)NMDAR (Glutamate receptor ionotropic, NMDA)KCNQ1 (Potassium voltage-gated channel subfamily KQT member 1)SCN5A (Sodium channel protein type 5 subunit alpha)NaV alpha (Voltage-gated sodium channel alpha subunit family)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)SCN10A (Sodium channel protein type X alpha subunit)SCN11A (NaV1.9)SCN2A (Voltage-gated sodium channel protein type 2 subunit alpha)SCN3A (Sodium channel protein type 3 subunit alpha)SCN4A (Voltage-gated sodium channel protein type 4 subunit alpha)SCN8A (NaV1.6)SCN9A (Sodium channel protein type 9 subunit alpha)
Beyond the preview
Go deeper on HYR-PB21 (bupivacaine liposome).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HYR-PB21 (bupivacaine liposome).